These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28251667)

  • 1. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.
    Krauwinkel W; Noukens J; van Dijk J; Popa S; Ouatas T; de Vries M; Phung D; Gibbons J; Mordenti J; Mateva L
    J Clin Pharm Ther; 2017 Jun; 42(3):268-275. PubMed ID: 28251667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Pharmacokinetic Studies of Enzalutamide.
    Gibbons JA; Ouatas T; Krauwinkel W; Ohtsu Y; van der Walt JS; Beddo V; de Vries M; Mordenti J
    Clin Pharmacokinet; 2015 Oct; 54(10):1043-55. PubMed ID: 25917876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
    Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
    Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
    Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
    Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Safety of Enzalutamide in Healthy Chinese Male Volunteers.
    Liu YM; Wu P; Fukushi R; Yamada S; Chen Q
    Clin Ther; 2019 Feb; 41(2):261-268. PubMed ID: 30642613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.
    Abbas R; Chalon S; Leister C; El Gaaloul M; Sonnichsen D
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):123-32. PubMed ID: 23053269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
    Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
    Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Ma H; Xu W; Ni J; Zhao N; Tang S; Li S; Cai T; Xiu J; Kang X; Gao S; Zhang L; Zhou T
    Prostate; 2022 Feb; 82(2):276-285. PubMed ID: 34807458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment.
    Csonka D; Hazell K; Waldron E; Lorenzo S; Duval V; Trandafir L; Kobalava ZD
    J Clin Pharmacol; 2016 Mar; 56(3):316-23. PubMed ID: 26183800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
    Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
    Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
    Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
    Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
    Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.